Valuation: Plasmatech Biopharmaceuticals Inc

Market Cap 35Cr 30Cr 28Cr 26Cr 48Cr 3.33TCr 49Cr 330.38Cr 128.47Cr 1.67TCr 130.76Cr 127.93Cr 5.54TCr P/E 2026 *
-6.44x
P/E 2027 * -32.6x
Enterprise Value 35Cr 30Cr 28Cr 26Cr 48Cr 3.33TCr 49Cr 330.38Cr 128.47Cr 1.67TCr 130.76Cr 127.93Cr 5.54TCr EV / Sales 2026 *
6.38x
EV / Sales 2027 * 2.92x
Free-Float
79.56%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Plasmatech Biopharmaceuticals Inc

Manager TitleAgeSince
Chief Executive Officer 50 15/10/2021
Director of Finance/CFO 42 14/03/2022
Chief Tech/Sci/R&D Officer - 20/10/2025
Director TitleAgeSince
Director/Board Member 58 01/03/2006
Director/Board Member 64 25/03/2021
Director/Board Member 63 19/04/2021
Change 5-day change 1-year change 3-year change Capi.($)
-0.55%+2.95%+44.96%-0.18% 8.33TCr
-4.33%+115.66%+448.38%+23.40% 5.79TCr
+0.48%+23.89%-21.93%-35.75% 5.78TCr
+1.42%+1.61%-0.67%+34.08% 5.17TCr
-0.77%+3.63%+11.51%+167.84% 4.93TCr
+0.64%+4.37%+60.09%-16.82% 3.2TCr
+0.15%+3.75%+51.17%+99.49% 2.59TCr
-2.83%+6.08%+0.05%+223.58% 2.27TCr
-1.74%+2.63%+55.54%+107.34% 1.69TCr
Average -0.82%+20.75%+72.12%+67.00% 4.42TCr
Weighted average by Cap. -0.74%+25.31%+83.44%+45.91%

Financials

2026 *2027 *
Net sales 5.46Cr 4.68Cr 4.38Cr 4Cr 7.55Cr 522.88Cr 7.63Cr 52Cr 20Cr 262.56Cr 21Cr 20Cr 868.71Cr 12Cr 10Cr 9.56Cr 8.74Cr 16Cr 1.14TCr 17Cr 113.1Cr 44Cr 573.19Cr 45Cr 44Cr 1.9TCr
Net income -5.4Cr -4.63Cr -4.33Cr -3.96Cr -7.48Cr -517.5Cr -7.56Cr -51Cr -20Cr -259.86Cr -20Cr -20Cr -859.78Cr -91.23L -78.18L -73.14L -66.87L -1.26Cr -87Cr -1.28Cr -8.65Cr -3.37Cr -44Cr -3.43Cr -3.35Cr -145.13Cr
Net Debt - -
Logo Plasmatech Biopharmaceuticals Inc
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. The Company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa. Its fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. Its development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Its AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Its pipeline programs include ABO-504 (Stargardt disease), ABO-503 (X-linked retinoschisis), ABO-505 (autosomal dominant optic atrophy), UX111 (Sanfilippo Syndrome Type A (MPS IIIA)), TSHA-102 (Rett Syndrome), and TSHA-118 (Infantile Batten Disease (CLN1 Disease)).
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-